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Death receptor 3 is a proinflammatory member of the immunomodulatory tumor necrosis factor receptor superfamily, which has been
implicated in several inflammatory diseases such as arthritis and inflammatory bowel disease. Intriguingly however, constitutive DR3
expression has been detected in the brains ofmice, rats, and humans, although its neurological function remains unknown. Bymapping
the normal brain expression pattern of DR3, we found that DR3 is expressed specifically by cells of the neuron lineage in a developmen-
tally regulated and region-specific pattern. Behavioral studies on DR3-deficient (DR3ko) mice showed that constitutive neuronal DR3
expression was required for stable motor control function in the aging adult. DR3ko mice progressively developed behavioral defects
characterized by altered gait, dyskinesia, and hyperactivity, which were associated with elevated dopamine and lower serotonin levels in
the striatum. Importantly, retrograde tracing showed that absence ofDR3 expression led to the loss of corticostriatal innervationwithout
significant neuronal loss in aged DR3ko mice. These studies indicate that DR3 plays a key nonredundant role in the retention of normal
motor control function during aging in mice and implicate DR3 in progressive neurological disease.
Introduction
The process of aging in the brain is complex and characterized by
progressive alterations to neural signaling pathways affecting be-
havior (O’Sullivan et al., 2001; Andrews-Hanna et al., 2007). Age-
related declines in motor control function appear to reflect
environmental and genetic components altering neuron lifespan
and function (Mattson et al., 2002; Heuninckx et al., 2005;
Yankner et al., 2008). Continued motor control function and
spatial awareness are critically reliant upon neuronal signaling
between the cortex, which translates sensory input, and the
striatum (Goldman-Rakic, 1987; Rakic, 1988), which medi-
ates motor and cognitive processes (Goldman-Rakic, 1987;
Dube´ et al., 1988; Rakic, 1988; Albin et al., 1989; Smith et al.,
1994; Groenewegen, 2003; Grahn et al., 2008). The neurotrans-
mitter dopamine plays a primary role in the conduction of all
motor control signaling within the striatum (Di Matteo et al.,
2008; Palmiter, 2008; Yao et al., 2008). The processes that govern
the homeostatic maintenance of these neural pathways following
their formation in the aging adult are poorly understood.
Death receptor 3 (DR3, Wsl-1, Apo3, LARD, TRAMP,
TNFRSF25, TR3) (Chinnaiyan et al., 1996; Kitson et al., 1996;
Marsters et al., 1996; Bodmer et al., 1997; Screaton et al., 1997) is
a member of the tumor necrosis factor receptor superfamily
(TNFRSF), a group of structurally related immunomodulatory
cytokine receptors capable of triggering NF-B induction and/or
caspase activation (Ashkenazi and Dixit, 1998; Mackay and
Kalled, 2002). DR3 along with its ligand TNF-like factor 1A
(TL1A) has been described as proinflammatory in severalmurine
disease models (Al-Lamki et al., 2003; Bamias et al., 2006; Bull et
al., 2008; Fang et al., 2008; Meylan et al., 2008; Pappu et al., 2008;
Takedatsu et al., 2008) and in chronic human diseases such as
inflammatory bowel disease and rheumatoid arthritis (Osawa et
al., 2004; Papadakis et al., 2005; Bamias et al., 2006; Borysenko et
al., 2006; Cassatella et al., 2007). In the brain, increased DR3
expression has been reported in ischemic rats (Harrison et al.,
2000) and humanAlzheimer’ disease (Newman et al., 2000), sug-
gesting this receptor contributes to neuropathology. Intriguingly
however, endogenous DR3 expression is also observed in the
brain of normal mice, rats, and humans (Marsters et al., 1996;
Wang et al., 2001b; O’Keeffe et al., 2008). Furthermore, such basal
expression may be neurologically important as some TNFRSF
members appear to facilitate normal neuronal differentiation
and survival (Kojima et al., 2000; Nieoullon and Coquerel,
2003; Graybiel, 2005; Ishiguro et al., 2007; O’Keeffe et al., 2008).
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Collectively, these observations suggest basal DR3 brain expres-
sion may play an important role in normal neuronal function.
In this study, we addressed the physiological role ofDR3 in the
adult brain by examining the behavior of DR3ko mice during
aging. We report that adult DR3ko mice spontaneously develop
severe behavioral defects characterized by a progressive decline in
highermotor control functions with advancing age. Importantly,
adult neuronal DR3 expression was found to be critical for con-
tinued maintenance of striatal neurotransmitter expression and
for stable neuronal contact between the cortex and the striatum.
Materials andMethods
Mice. DR3ko mice on a C57BL/6 background were previously generated
at, and colony-founding animals supplied by, Cancer Research UK
(Wang et al., 2001a). All United Kingdom (UK)-based animal experi-
ments were subject to local ethical review and conducted according to
personal, project, and institutional licenses under the UK Animals (Sci-
entific Procedures) Act 1986. For experiments performed in Spain,
animal-related procedures were in accordance with the National Insti-
tutes of Health guidelines for the care and use of laboratory animals and
approved by the local animal care committee of the Universitat de Bar-
celona and by the Generalitat (Autonomous Government) of Catalonia.
Histological analysis. Tissue preparation, tyrosine hydroxylase (TH)
and NeuN immunohistochemistry on free-floating sections, and subse-
quentmorphometrywere performed as described previously (Kelly et al.,
2007). Brain region volume and cell number were based on NeuN/TH
staining anddeterminedusing theOlympusCASTgrid stereology system
on a 1:12 series using previously described methods. At high magnifica-
tion, brain region volume, neuron number, and the density of TH im-
munostainingweremeasured on four anatomicallymatched sections per
animal using the40 objective (Leica DMRB microscope, Leica Micro-
systems) and Scion image system.
Immunohistochemical detection and colocalization of NeuN, GFAP, and
-Gal inDR3het andDR3komice. Indirect fluorescent immunocytochem-
istry was performed using standard protocols with primary antibodies
directed against neuronal nuclei (NeuN, PharMingen), -galactosidase
(-Gal, Millipore Bioscience Research Reagents), and glial fibrillary
acidic protein (GFAP, DAKO). Sections were counterstained with
Hoechst 33342 (2 g/ml; Sigma) to label nuclei before visualization by
confocal microscopy on an Olympus IX70 microscope linked into an
Ultraview system (Perkin and Elmer).
Brain mapping of -Gal expression in DR3het and DR3ko mice. Mice
were generated by replacement of the DR3 gene with a cassette including
an internal ribosome entry site (IRES) and lacZ poly(A), allowing visu-
alization using X-gal staining. Brains fromDR3het and DR3ko mice were
removed, flash frozen in liquid nitrogen (LN2), coronally sectioned at 10
m thickness, and stored at80°C. Whole mouse brains being assayed
for-Galwere removed, fixed in 4%PFA, and thenwashed extensively in
PBS. Sections being assayed for -Gal were prepared as described above,
immersed in X-gal staining solution for 18–24 h at 37°C, counterstained
with Nuclear Fast Red (Vector Laboratories), and hard mounted using
standard techniques. Images were taken using a Nikon light microscope,
Kodak EPY-64T color slide film, or a Nikon-based digital camera imag-
ing system.
Reverse transcriptase-PCR. DR3 and TL1A expression in the brains of
8- to 12-week-old mice was examined by reverse transcriptase (RT)-
PCR. Brains from8- to 12-week-oldmiceweremicrodissected on ice into
the hippocampus, basal ganglia, cortex, cerebellum, dentate gyrus, and
colliculi. Total RNA was extracted from tissues or cultured cells using
RNeasy (Qiagen) and cDNA prepared using Superscript II (Invitrogen)
according to the manufacturer’s instructions. PCR was performed ac-
cording to the following cycle preceded with Taq activation for 15min at
95°C: step 1, 94°C for 45 s, an annealing step (temperature dependent
upon primers) for 30 s, and 72°C for 45 s. The reactionwas terminated by
10min at 72°C and then kept at 4°C until required. PCR primers, anneal-
ing temperature, and expected product size for the amplification of
TNFRSF members and TL1A are shown in supplemental Table 1 (avail-
able at www.jneurosci.org as supplemental material). The amount of
cDNA in each PCRwas assessed by additionally amplifying a fragment of
the GAPDH cDNA. Reaction products were resolved on a 1.2% agarose
gel and stained with ethidium bromide before UV visualization. Band
intensities were measured using Labworks analysis software.
Gait, balance, and open-field analysis. Gait and balance analysis was
performed using footprint pattern analysis as previously described in the
presenceor absenceof a1 cmrodbalancebeamelevatedby3cm(Dunnett et
al., 1998). Open-field testing was performed as previously described
(Torres et al., 2007). Open-field analysis was conducted on scaled draw-
ings of animal movement produced by frame-to-frame examination of
captured digital footage. Crossovers were determined by counting the
combined number of times mice crossed their own paths during obser-
vation per min during a 10 min observation period.
Neurochemistry.Male DR3het andDR3komice 3 and 18months of age
were killed, and their brains were removed and microdissected on ice.
Brain tissues were weighed, snap frozen using LN2, and sent for com-
mercial analysis (RenaSci Consultancy) by HPLC to determine the
level of 5-hydroxyindoleacetic acid (5-HIAA), serotonin (5-HT), 3,4-
dihydroxyphenylacetic acid (DOPAC), dopamine, homovanillic acid
(HVA), and noradrenaline (NA).
Retrograde tracing. Intracerebral injection of the retrograde tracer Flu-
orogold (FG) (Fluorochrome) was performed in 3- and 18-month-old
mice as previously described (Pineda et al., 2005). In brief, animals were
anesthetized and placed in a stereotaxic apparatus (Stoelting), and Flu-
orogold solution (1% in PBS) was injected into the striatum at the fol-
lowing coordinates: A/P0.5 mm, L2mm from bregma; and D/V 2.7
mm from dura; incisor bar set at3 mm. After 2 d, mice were perfused
transcardially with 4% paraformaldehyde in PBS, cryoprotected with
30% sucrose, and frozen in dry-ice-cooled isopentane. Coronal sections
(30m)were cut on a cryostat andmountedwithMowiol (Calbiochem).
Statistical analysis. Statistical analyses were made with either Student’s
t tests or t tests assuming unequal variance if normal distributions could
not be assumed. A  2 test was used to compare frequency of run com-
pletion data. Unless stated otherwise, plotted data represent mean 
SEM; p values of0.05 were considered significant.
Results
DR3 expression in the brain is neuron specific
Analysis of DR3 mRNA transcript levels in mouse (Wang et al.,
2001b; O’Keeffe et al., 2008) and rat (Harrison et al., 2000) tissue
has previously shown thatDR3 is expressed using alternate length
transcripts in the brain compared to lymphoid tissue. In the ab-
sence of a range of antibodies that are confirmed to recognize all
variants of murine DR3 protein in histological sections, we used
the -Gal gene expressed under the control of the murine DR3
promoter (Wang et al., 2001a), to investigate the regional and
developmental pattern of putative DR3 protein expression in the
brains of mice. DR3 gene expression was first detected neonatally
after d5 after birth and was rapidly upregulated by d9 after par-
turition (Fig. 1). This expression pattern was retained through
early to late adulthood (Fig. 2A–C). To explore the expression
pattern of DR3 in adult DR3het andDR3komice,matched-Gal-
andH&E-stained coronal brain serial sections (10m thickness)
were compared, allowing construction of DR3 promoter expres-
sion maps. Positionally, -Gal expression was detected between
the piriform cortex throughout the brain of transgenic mice to
the caudal mesencephalon, disappearing at the transition to the
cerebellum. In mice, the density and pattern of -Gal staining
was region specific: substantial numbers of -Gal cells were
present within the hippocampal and cortical regions, but expres-
sion was undetectable in the striatum, substantia nigra, and cer-
ebellum (Fig. 2A–C). In the hippocampus, nearly all granular
(dentate gyrus) and pyramidal cells (CA1–CA3 fields) stained
densely for -Gal, whereas coloration between these layers was
less frequent. In the cortex, -Gal cells were diffuse but present
in all layers (Fig. 2A,B). The-Gal staining pattern found in the
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brains of DR3ko mice was largely mirrored in age-matched
DR3het mice, although weaker in intensity. Intriguingly, how-
ever, a severalfold greater number of -Gal cells were found
throughout the cortex of DR3ko than in that of DR3het mice,
suggesting an attempt to express the DR3 gene in its absence
(Fig. 2A).
To confirm the basal regional pattern ofDR3 expression in the
brain revealed by -Gal, an adult DR3wt brain was microdis-
sected into regions and DR3 mRNA expression assessed by RT-
PCR. DR3 transcripts were expressed at high levels in the cortex,
hippocampus, and dentate gyrus but remained undetectable in
the cerebellum of adult DR3wt mice, consistent with DR3 local-
ization visualized by -Gal expression studies (Fig. 2D; supple-
mental Fig. 1, available at www.jneurosci.org as supplemental
material). Somemessagewas obtained from theDR3wt basal gan-
glia, but -Gal staining was not observed in this region in DR3het
andDR3komice. As expected, no expression ofDR3mRNA tran-
script was detected in DR3komice (supplemental Fig. 1, available
at www.jneurosci.org as supplemental material). We next used
immunohistochemical studies to define the lineage of cells within
the brain. InDR3hetmice, analysis revealed that-Gal expression
colocalized almost exclusively with the neuron-specific marker,
NeuN, and not with the astrocyte and glial cell marker, GFAP
(Fig. 2E). These results indicate that DR3 expression is neuron-
lineage specific, developmentally regulated, and regionally de-
fined in the adult mouse brain.
We next sought to determine the level and pattern of TL1A
mRNA expression, the only substantiated ligand for DR3
(Kaptein et al., 2000; Migone et al., 2002; Bossen et al., 2006), in
the brains of adult mice. Interestingly, expression of transcripts
for TL1Amirrored that of DR3with the highest expression found
in the cortex, and the lowest expression detected in the cerebel-
lum (Fig. 2D). More moderate TL1A mRNA expression was
found in the hippocampus, colliculi, basal ganglia, and dentate
gyrus (Fig. 2D). The survival, structure, and function of neurons
in the brain is known to be critically dependent on glial cells
(Nave and Trapp, 2008; Fiacco et al., 2009). Several studies have
identified astrocytes as being responsible for intensive produc-
tion of several TNF family ligands following a range of stimuli in
vitro and in vivo (Sawada et al., 1989; Badie et al., 2001; Shin et al.,
2002; Yan et al., 2007). We therefore purified astrocytes from the
cortex of DR3wt mice and examined whether TL1A mRNA was
expressed by these cells ex vivo. Cultured astrocytes expressed low
levels of transcript for murine TL1A, which was upregulated rap-
idly by TNF, suggesting that these cells may be responsible for
constitutive low level provision of TL1A to local neurons within
the cortex (supplemental Fig. 2, available at www.jneurosci.org as
supplemental material). We also examined whether the expres-
sion levels of a range of other TNFRSF members (TNFR1, FAS,
DR4/6, DR5, and p75NTF) or the DR3 modulator, silencer of
death domain (SODD), might be altered in the absence of DR3
expression. Expression of mRNA for these proteins was compa-
rable between DR3het and DR3ko mice by RT-PCR, indicating
that loss of neuronal DR3 expression is not compensated for by
upregulation of other death domain TNFRSF members (supple-
mental Fig. 3, available at www.jneurosci.org as supplemental
material). Collectively, these studies suggest that TL1A is ex-
pressed by glial cell populations in the absence of inflammation,
while expression levels of other TNF family members in the cor-
tex ofDR3komice remain unaltered. The presence of constitutive
cortical TL1A expression in the absence of inflammation suggests
that TL1A/DR3 signaling may play an important role in normal
neuronal function or maintenance in the cortex.
Progressive loss of motor control in aging DR3ko mice
To assess the role of constitutive DR3 expression in normal brain
function, the behavior of DR3wt, DR3het, and DR3ko mice was
monitored and assessed during aging. Initial observations re-
vealed that DR3ko mice developed a progressive behavioral dis-
order characterized by abnormal gait, rapid head movement,
apparent disorientation, dyskinesia, and body tremor that was
triggered by environmental change such as handling, none of
which were seen in DR3wt or DR3het mice. Occasionally, early
aged founder mice were also found to suffer from seizures. Be-
havioral abnormalities were detectable in a proportion of DR3ko
mice as young as 4 months, and the sex-independent disorder
was 100%penetrant by 18months of age (Fig. 3). To quantify this
defect, mice were timed traversing a Perspex corridor, and mea-
surements of stride length, width, and distance between hindpaw
and forepaw placement (overlap) were made for mice aged 3
(young) and 24 (old) months. While run times between young
DR3het andDR3ko and oldDR3hetmice did not differ, oldDR3ko
mice took significantly longer to complete their runs (DR3ko
6.8 1.3 s vsDR3wt 3.4 0.7 s;F(1,10) 5.84, p 0.04) (Fig. 4A).
Figure 1. Developmental DR3 expression in the early postnatal murine brain. Shown is DR3
promoter-driven -Gal expression (X-Gal, blue) in the brains of early postnatal DR3 ko mice.
Lowmagnification is shown in left-hand panels; highmagnification in the right-hand panels at
postnatal days 1 to 9 (P1 to P9) as indicated. Scale bars: 500m for left-hand panels; 100m
for right-hand panels. The dentate gyrus is shown in each case with images representative of 2
animals per age.
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An age-dependent difference was also detected in the gait mea-
surements of DR3ko mice, a representation of which is shown in
Figure 4B. Only old DR3ko mice exhibited significantly short-
ened forepaw stride lengths (DR3ko 5.1 1.1 cm vs DR3wt 6.3
0.5 cm; F(1,10)  6.17, p  0.04), broader hindpaw stride width
(DR3ko 3.00.3cmvsDR3wt2.60.2cm;F(1,10)9.84, p 0.02),
and decreased overlap relative to matched controls (DR3ko
1.4 0.6 cm vsDR3wt 0.7 0.2 cm; F(1,10) 8.11, p 0.02) (Fig.
4C). We also explored whether the balance of DR3ko mice might
also be impaired by defective motor con-
trol as found for some models of neuro-
logical disease (Fernagut et al., 2004;
Truong et al., 2006). Aged DR3het mice all
traversed the 60 cm long balance beam on
all three runs in an average time of 11.4
0.6 s. In contrast, the DR3ko mice had
much greater difficulty completing the
task: only two of the eight mice succeeded
in crossing the beam within the 120 s ob-
servation period on all three runs, three
failed on one or two occasions to cross,
and three failed on all three occasions
(Fig. 5A). For purposes of analysis, failed
runs were allocated a maximum crossing
time of 120 s, yielding a group mean la-
tency to cross of 83.0 15.7 s, which was
significantly longer than that taken by the
DR3het group (F(1,13) 18.09, p 0.003)
(Fig. 5B). While loss of footing by well
balanced adult DR3het mice was rare,
movement by DR3ko mice was marked by
frequent imbalance, foot slippage, and
stationary behavior (Fig. 5C).
We next examined the movement and
exploratory behavior of DR3ko mice by
comparing the activity of transgenic mice
during open-field tests using a graduated
1 m Perspex square. Compared to 24-
month-old DR3het controls, similarly aged
DR3ko mice exhibited hyperactivity and
increased complexity of movement char-
acterized by rapid, abrupt changes in for-
ward direction and path crossing with
some animals showing strong circling
behavior (supplemental Videos 1–3, avail-
able at www.jneurosci.org as supplemental
material) (Fig. 6A). In a 10min observation
period, DR3ko mice traversed an average
of 250% more accumulative open space,
covering 89 17m relative to DR3het con-
trols, which traversed 35  5 m (F(1,10) 
8.87, p 0.02) (Fig. 6B). The relative com-
plexity of DR3ko mice open-field activity
also increased compared to DR3het mice as
determined by the frequency mice crossed
their own path, with DR3ko mice averaging
this readout 286  86 times over 10 min,
14 times more frequently than their
DR3het counterparts who averaged this
20 6 times (F(1,10) 9.47, p 0.02) (Fig.
6B). This increased locomotor complex-
ity was not due to their hyperactivity as
the average distance traveled before a
crossover event was significantly shorter in DR3ko mice than in
DR3het controls (DR3ko 0.41  0.07 m vs DR3wt 2.5  0.5 m;
F(1,10)  16.83, p  0.003) (Fig. 6C). No directional preference
was observed in the circling behavior of individual mice during
open-field tests regardless of age or sex. Similar results were ob-
tained with DR3ko mice that had been crossed with CD1 (out-
bred)mice for two generations (data not shown), demonstrating
that the dysfunction was not due to a specific genetic back-
ground. Collectively, these results confirm that DR3ko mice
Figure 2. DR3 and TL1A expression in the adult brain. A, B, Representative images of-Gal staining in adult DR3 ko and
DR3 het mice in different areas of the brain. Number of -Gal-stained cells increased in the cortex of DR3 ko mice, particu-
larly in prefrontal areas such as the anterior olfactory nuclei (Ai, Aii) and generally across other areas such as the primary
motor cortex (Biv, Bv), but remained high and unchanged in the dentate gyrus (Bvi, Bvii). Comparative expression is
shown for the prefrontal (Aiii) andmotor cortex (Bviii). Areas in which-Gal expression was detected are shown for DR3 ko
in yellow and DR3 het in blue. Filled areas show high-density-Gal staining. Areas fromwhich high-magnification sections
are shown (Ai, Aii, Biv–Bvii) are indicated by numbers with red squares for DR3 ko and green squares for DR3 het animals.
C, DR3 expression in DR3 het brain as detected using the -Gal reporter. BG, Basal Ganglia; Co, cortex; Cb, cerebellum; DG,
dentate gyrus; Hf, hippocampal formation. D, Expression of DR3 and TL1A mRNA in the indicated areas of the brain as
measured by RT-PCR. GAPDH is shown as a loading control. E, Microscopy showing neuron-specific DR3 promoter-driven
-Gal expression in the dentate gyrus using immunofluoromicroscopy. Signals from -Gal overlap with NeuN (Ei–Eiii),
but not GFAP (Eiv–Evi).
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develop significant motor coordination problems, hyperactiv-
ity, and abnormal exploratory behavior in an age-dependent
manner.
Dysregulated dopamine and serotonin expression in the
striatum of aged DR3ko mice
We next determined whether the behavioral abnormalities ex-
hibited by aged DR3ko mice were associated with altered levels of
neurotransmitters in the brain. Brains from3- and 18-month-old
mice were microdissected into the cortex, striatum, hippocam-
pus, and cerebellum, and the levels of neurotransmitters assessed
by HPLC. Brains from DR3ko mice appeared histologically nor-
mal being devoid of apparent cellular infiltrates, lesions/plaques,
upregulated inflammatory markers, and apparent inflammation
as assessed by immunohistochemistry (unpublished observa-
tions). Weights of whole and individually dissected regions of
brain were also similar betweenDR3ko andDR3het animals (sup-
plemental Fig. 4, available at www.jneurosci.org as supplemental
material). YoungDR3ko andDR3wtmice (3monthsof age) showed
no significant differences in neurotransmitter levels in the brain, but
strikingly, we found that dopamine levels within the striatum of
18-month-old DR3ko mice were 60% higher than their DR3het
counterparts (DR3ko 15,546 1163 ng/g tissue vsDR3het 9768
2383 ng/g tissue; F(1,9)  5.32, p  0.05), while serotonin was
fourfold lower (DR3ko 77  21 ng/g tissue vs DR3het 328  81
ng/g tissue; F(1,9)  10.63, p  0.01) (Table 1). These changes
could not be explained by a failure of dopamine breakdown, as
the ratios of dopamine to dopaminemetabolites (DOPAC,HVA)
were unchanged (Table 1; supplemental Fig. 5, available at www.
jneurosci.org as supplemental material). Furthermore, it could
not be explained by upregulation of TH, the primary enzyme
responsible for dopamine production, as TH levels throughout
the brainwere comparable betweenDR3ko andDR3wt controls as
assessed by immunohistochemistry on coronally matched sec-
tions (Fig. 7A,B). These data demonstrate that despite an absence
of overt neurological pathology, agedDR3komice have profound
differences in striatal neurochemistry.
Corticostriatal innervation is DR3 dependent in aging
DR3ko mice
Current literature suggests that DR3 can control cell fate by ini-
tiating either proliferative or apoptotic signaling (Chinnaiyan et
al., 1996; Kitson et al., 1996; Marsters et al., 1996; Migone et al.,
2002). We therefore examined whether neuronal lifespan might
be altered in the absence of DR3 expression in vivo by examining
neuron numbers in aged mice. The number of NeuN cells
present in aligned sections from the brains of aged DR3het and
DR3ko mice showed no significant difference following two-
dimensional histological topographic analysis (Fig. 8A). The area
and thickness of individual layers or regions of the brain as cal-
culated by computer topography was also found to be similar
between DR3het mice and their controls (supplemental Table 2,
available at www.jneurosci.org as supplemental material). No
difference was also found in the number of apoptotic neurons in
Figure 3. Time course of development of observable gait disorders in DR3 ko mice. Propor-
tion of DR3 ko and DR3 het mice showing observable gait disorder with age. Numbers under the
graph represent numbers of mice per age group assessed.
Figure 4. Defects in gait in aged DR3 ko mice. Gait defects in 3-month- or 2-year-old mice
were compared using timed footprint and movement analysis. A, Average run time for young
and old mice. B, Representative footprints of DR3 ko and DR3 het mice are shown. C, Footprint
analysis showing stride length (i, ii) and stridewidth and overlap (iii, iv) of young (i, iii) and old
(ii, iv) mice. *Student’s t tests showed significant differences as indicated.
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the brains of adult DR3ko mice, compared to controls, which
were barely detectable (unpublished observations) in agreement
with others (Yang et al., 2008). Together, these data suggest that
DR3 plays no overt role in the normal determination of neuron
lifespan in adult mice in vivo.
Given that agedDR3komice had normal neuron numbers and
DR3was not expressed in the striatum,we next hypothesized that
corticostriatal innervation might be altered by the loss of neuro-
nal DR3 expression, as has been recently observed for another
TNFRSFmember, GITR (O’Keeffe et al., 2008). This was directly
assessed by injection of the retrograde axonal tracer FG into the
striatum of mice. The cortex of 18-month-old DR3ko mice had
significantly lower numbers of FG-labeled pyramidal cells than
similarly treated control animals (Fig. 8B,C). Overall, 25% of
corticostriatal contact had been lost in aging DR3-deficient mice
in the absence of continued cortical DR3 expression by neurons
as indicated by retrograde tracing (DR3ko 74.7 2.7% vs DR3wt
100  8.5% of normal cortical density; F(1,6)  8.25, p  0.03).
No significant differences were observed between young (3
months old)DR3wt (100 8%) andDR3ko (95 2%)mice (Fig.
8C). These results demonstrate that continued neuronal DR3
expression is important for the normal, long-term maintenance
of neuronal innervation between the cortex and striatum in adult
mice in the absence of appreciable neuron loss. It is less likely that
there is a developmental deficit, since there were no differences in
innervation density between 3-month-old animals.
Discussion
In this study, we demonstrate for the first time that DR3 is criti-
cally required for maintaining neural connectivity between the
cortex and striatum during aging, which is necessary for normal
motor control function. DR3ko mice develop a progressive loco-
motor disorder defined by deficits in coordinatedmovement and
gait, which emerges during early adulthood, appears sex indepen-
dent, and is 100%penetrant. The behavioral phenotype of DR3ko
mice resembles a milder form of that observed in jerker mice,
which carry a recessive point mutation that disrupts the expres-
sion of the actin-bundling protein espin in hair cell stereocilia
(Zheng et al., 2000). Because espin lies next to DR3 in themurine
genome, we studied espin protein expression byWestern blotting
and found no difference between DR3wt and DR3ko kidney, a
tissue in which small espin is found in brush border microvilli
(Bartles et al., 1998) (supplemental Fig. 6, available at www.
jneurosci.org as supplemental material). This suggests that espin
expression is unaffected inDR3komice and that the phenotype of
the mice is DR3 specific. Importantly, advancing loss of motor
control in DR3ko mice occurred through a relatively passive pro-
cess without the induction of apparent inflammation, alteration
to other TNFRSF brain expression levels or radical changes in
neuron number. Thus, we propose that low endogenous TL1A
stimulation of DR3 cortical neurons stimulates the mainte-
nance of interneuronal contact with adjoining dopaminergic or
serotonergic striatal neurons. Supporting this, we observed in
Figure 5. Defects in balance in aged DR3 ko mice. Balance was compared in 2-year-old
DR3 het and DR3 ko mice by timing of runs along a raised balance beam within a 60 cm run.
A, Completion frequency for DR3 het and DR3 ko mice.  2 test showed significant difference as
indicated.B, Average run times for DR3 het and DR3 komice, with animals not completing given
a maximum time of 120 s. Each point represents the average from 3 runs from an individual
animal. *Student’s t test assuming unequal variance showed significant differences as indi-
cated. C, Representative footprints of DR3 ko and DR3 het mice are shown.
Figure 6. Hyperkinesia and increasedmovement complexity in DR3 ko mice. A, Representa-
tive plots of themovement of digitally trackedmice in a 1m square open field over 1min (n
6–8 per group). S, Start; F, finish. B, Accumulative distance traversed (i, ii) and accumulative
frequency of path-crossing events (iii, iv) displayed by young (i, iii) and old (ii, iv) DR3 ko and
DR3 het mice during 10 min. C, Average distance traversed before mice crossed their own
paths. Each group included 4 – 8 mice, and data are representative of four experiments.
Asterisks in relevant panels indicate significance of Student’s t tests. Lines and error bars
represent mean SEM.
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vitro expression of TL1AmRNA fromcultured astrocytes isolated
from the cortex, the primary site of TL1A transcript expression in
vivo. How might TL1A promote DR3-dependent innervation?
One possibility is that TL1A may contribute directly to axon
growth or dendrite formation in aging neurons such as occurs
following FasL treatment of embryonic neurons (Zuliani et al.,
2006) and GITRL treatment of neonatal sympathetic neurons
(O’Keeffe et al., 2008). Alternatively, TL1A may increase neuron
excitability or alter ion channel signaling as has been shown for
TNF (Diem et al., 2001; Ogoshi et al., 2005; Ozaktay et al., 2006;
Czeschik et al., 2008). In such cases, more frequent neuronal
stimulation would be predicted to drive new synapse/dendrite
formation and stabilization (De Roo et al., 2008). Importantly,
our results suggests that the maintenance of adult neuronal cor-
ticostriatal projections formed earlier during development and
critical for motor control is dependent on the continued recep-
tion of low level DR3 signaling by neurons involved in these
contacts.
The expression of transcripts for TL1A throughout many
parts of the brain in a region-specific manner is also a novel
finding. Before this study, TL1A has been reported to be found in
serum (Bamias et al., 2008), human umbilical vein endothelial
cells (Yang et al., 2004), and myeloid and T-cells (Bamias et al.,
2003; Cassatella et al., 2007; Prehn et al., 2007; Meylan et al.,
2008). TL1A has been reported to have roles in mucosal immu-
nity (Papadakis et al., 2005), inflammatory bowel disease (Bamias
et al., 2006; Takedatsu et al., 2008), inflammatory arthritis
(Borysenko et al., 2006; Cassatella et al., 2007; Bull et al., 2008),
renal inflammation (Al-Lamki et al., 2008), asthma (Fang et al.,
2008; Meylan et al., 2008), and autoimmune encephalitis
(Meylan et al., 2008; Pappu et al., 2008). Since the brains of DR3-
deficient animals have normal cell numbers and appear devoid of
any inflammation or apparent neuropathology, this suggests that
cerebral mechanisms exist to dampen neuronal DR3 responsive-
ness, which is likely to be very threshold or age sensitive. This
might be expected as TL1A seems to be constitutively produced
by cells within the brain in regions whereDR3 neurons cohabit.
Progressive behavioral defects in DR3ko mice paralleled the
differential expression of striatal neurotransmitters with in-
creased dopamine and a corresponding serotonin reduction. Do-
pamine signaling appears essential for motivated behavior as
shown by severe defects in feeding, motor control, and reward-
based learning apparent in Dopamine ko mice (Zhou and
Palmiter, 1995; Palmiter, 2008). Serotonin receptor family-
deficient mice also display altered locomotion and behavior
(Lesch et al., 2003). Moreover, serotonin and dopamine imbal-
ances are prominently associated with human neurological dis-
Table 1. Concentration of neurochemicals in the DR3 ko and DR3het brain
Neurochemical concentration (ng/g wet weight)a
Area of brain 5-HIAA 5-HT DOPAC DOPAMINE HVA NA
Hippocampus
Young DR3 het 448 36 661 26 12 1* 24 5 40 3 584 31*
Young DR3 ko 392 40 635 40 16 1* 24 2 43 1 496 20*
Old DR3 het 479 48 602 100 8 4 43 16b 28 5 491 54
Old DR3 ko 542 18 695 38 0.4c 51c 31 5 572 29
Mesencephalon
Young DR3 het 646 25 1261 30 126 9 368 35 249 26 746 25
Young DR3 ko 587 17 1173 26 138 16 359 56 234 33 738 49
Old DR3 het 696 53 945 46 52 14 189 32 122 21 638 44
Old DR3 ko 663 61 907 32 69 7 190 19 130 10 754 55
Striatum
Young DR3 het 329 44 488 35 627 73 5589 190 1282 175 153 24
Young DR3 ko 288 19 479 31 782 73 5952 188 1359 160 156 49
Old DR3 het 290 45 328 81* 743 158* 9768 2383* 717 106* 221 35
Old DR3 ko 340 31 77 21* 1251 84* 15546 1163* 1047 66* 197 27
Rest of brain
Young DR3 het 267 19 445 16 81 6 485 39 191 13 515 24
Young DR3 ko 240 18 438 8 92 3 489 42 186 9 509 10
Old DR3 het 384 19 431 22 189 20* 542 61 130 14 562 43*
Old DR3 ko 349 14 432 41 131 9* 524 36 147 9 439 31*
Young mice were 3 months of age; old mice were 18 months of age; experiments on young and old animals were carried out at different times, so only age-matched animals were compared statistically.
aValues are mean SEM, calculated from 5 young DR3 ko, 5 young DR3 het, 6 old DR3 ko, and 5 old DR3 het male mice unless otherwise stated.
bValue calculated from 3mice (others gave values below detection of the assay).
cValue calculated from 1mouse (others gave values below detection of the assay).
*Student’s t test between DR3 het and DR3 ko values showed significance at p 0.05.
Figure 7. Expression of tyrosine hydroxylase in the brain. A, Immunohistochemistry show-
ing TH expression in DR3 ko (i) and DR3 wt (ii) mice. B, Summary data showing no differ-
ence in TH expression at all matched levels throughout the striatum between DR3 ko and
DR3 wt mice.
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orders ranging from Parkinson’s disease to schizophrenia and
circling in mice (Nieoullon and Coquerel, 2003; Ishiguro et al.,
2007; Di Matteo et al., 2008). The biosynthesis of dopamine oc-
curs in a two stage process inwhich L-tyrosine is first converted to
L-DOPA, by the enzyme TH, and then L-DOPA is converted to
dopamine, by the enzyme DOPA decarboxylase (Zhou and
Palmiter, 1995). Striatal dopamine levels appear dependent on
production by DA neurons projected from the substantia nigra
(SN) as changes in striatal dopamine often reflect alteration to SN
neuron number (Kramer et al., 2007). In aged DR3ko mice, how-
ever, we show that striatal dopamine levels were elevated to 160%
in the absence of any change to brain neuron numbers or alter-
ation in the level or pattern of TH expression.We also found that
the levels of two products generated from the breakdown of do-
pamine, DOPAC and HVA, were found in normal ratios, sug-
gesting that a failure of striatal dopamine metabolism was not
responsible for increase levels of this neurotransmitter. It has
been suggested that continued dopamine expression is important
for the correct maintenance of corticostriatal synapses, as unilat-
eral destruction of dopaminergic striatal input leads to innerva-
tion failure (Arbuthnott et al., 2000).However, whether a specific
loss of corticostriatal innervation can induce a corresponding
upregulation of striatal dopamine remains unclear. Alternatively,
neurotransmitter dysregulation in DR3ko mice may reflect the
absence of direct DR3-dependent alteration of neurotransmitter
production or subsequent synaptic sensitivity as triggered by
TNF (Schafers and Sorkin, 2008). Both models are consistent
with the hypothesis that behavioral defects in dopamine-
dependent disordersmay reflect corticostriatal pathway dysfunc-
tion, as found in DR3ko mice, rather than just changes to cortical
activity (Costa et al., 2006).
Striatal serotonin levels were also reduced by 73% in adult
DR3ko mice. There is evidence to suggest that excessive dopa-
mine production can inhibit serotonin production by serotoner-
gic neurons in the striatum in vivo leading to behavioral defects.
Many Parkinson’s disease patients receiving long-term L-DOPA
treatment suffer motor control loss associated with dopamine
dysregulation (Cenci and Lindgren, 2007). Similarly, dopamine
uptake, production, storage, and release can supplant and deplete
serotonin in striatal serotonin neurons following chronic
L-DOPA treatment in several models (Kannari et al., 2006;
Yamada et al., 2007; Carta et al., 2008). We therefore suggest that
excessive striatal dopamine production in DR3ko mice is down-
regulating serotonin expression and that neuronal DR3 signaling
is likely to be a major inhibitory dampener suppressing dopa-
mine induction in vivo.
The role of basal TNFRSFmember brain expression and func-
tion is an emerging field with few published studies. In vitro,
select TNFSRF members have been shown to promote nerve
growth and function (Shao et al., 2005; Czeschik et al., 2008;
Hayashi et al., 2008; Hou et al., 2008; O’Keeffe et al., 2008). Con-
stitutive brain expression of some TNFRSF receptors has also
been reported (Yan and Johnson, 1988; Pan et al., 1998; Eby et al.,
2000; Kojima et al., 2000; Tan et al., 2002; Pispa et al., 2003; Shao
et al., 2005; Zuliani et al., 2006; Hamill et al., 2007; Catts et al.,
2008; Harry et al., 2008; Hou et al., 2008; O’Keeffe et al., 2008),
but the neurological function of most members remains un-
known. The extensive behavioral and neurochemical defects ex-
hibited by DR3ko mice are unique among TNFRSFko mice. For
example, TNFR1ko mice have normal striatal dopamine/metab-
olite levels (Leng et al., 2005) and locomotor activity, exhibiting
standard behavioral responses in several tests (e.g., open field and
Porsholt swim) (Simen et al., 2006; Quintana et al., 2007; Baracchi
and Opp, 2008). Why DR3ko mice, among TNFRSF-deficient
animals, uniquely develop severe and progressive neurological
defects requires further study but probably reflects receptor dif-
ferences in function and endogenous age-related expression. In
this respect, we first show that continued neuronal DR3 signaling
functions by uniquely promoting region-specific (corticostriatal)
brain innervation. Second and regardless of themechanism, basal
neuronal DR3 appears to functionally regulate the expression of
two key neurotransmitters required for movement and behavior,
dopamine and serotonin. Thirdly, we note that stable postnatal
neuronal DR3 expression appears more intense and widespread
in the cortex and hippocampus than most TNFRSF members in
brain regions with motor control pathway function. No other
TNFRSF member has been similarly reported to functionally
promote the stabilization of preexisting adult neural pathways
and regulate striatal neurotransmitter expression under normal
Figure 8. Alterations in corticostriatal innervation in the absence of changes of neuronal
number in DR3 ko mice. A, Stereological counting of NeuN cells showed no difference be-
tween DR3 ko and DR3 hetmice at 4 differentmatched levels in the brain. Data aremean SEM
from n 9 mice. B, C, Retrograde tracing of innervation into the striatum. B, Representative
images from the cortex of 18-month-old DR3 ko (i) and DR3 wt (ii) mice. Scale bars, 100
m. C, Young (3 months of age) DR3 ko and DR3 wt mice showed equivalent corticostriatal
innervation, while old (18 months of age) DR3 ko mice showed a reduction in corticostria-
tal innervation compared to age-matched DR3 wt mice. Data are percentage of the age-
matched DR3wt mean SEM from n 4 mice. Statistical significance of *p 0.03 using a
Student’s t test.
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conditions in vivo. TNF, though, has been shown to act as a
gliotransmitter, altering synaptic transmission (Stellwagen et al.,
2005) and controlling synaptic strength (Beattie et al., 2002) and
scaling (Stellwagen and Malenka, 2006), while other proinflam-
matory cytokines such as IL-1 can influence synaptic plasticity
(Ross et al., 2003). The interactions between TL1A and these
cytokines in the brain are poorly understood and remain an im-
portant area of further investigation.Our data are consistent with
the suggestion that the key neurological function of individual
TNFRSF receptors is likely to be developmentally, functionally,
and regionally compartmentalized within the brain.
In this report, we identify neuronal DR3 signaling as being
mandatory for normal striatal neurotransmitter expression and
maintenance of corticostriatal neural pathways, which are essen-
tial for normal motor control function in the aging adult. How
DR3 signaling provides pathway stabilization cues to these neural
networks remains an important issue to be resolved; however, the
observation that aging DR3komice acquire defective neurotrans-
mitter expression and progressive motor control loss provides a
unique insight into this proinflammatory receptor. Importantly,
this study demonstrates that DR3 plays a key nonredundant role
in behavior and normal adult brain homeostasis, further expand-
ing upon the essential roles that TNFSFR members play within
the mammalian body. As such, we identify DR3 as a primary
molecular target for future neuromodulatory and neurodegen-
erative disease research.
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